WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 7 fonti

Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.

Raccontata dacnbc.comft.comcincodias.elpais.comforbes.comtheguardian.combbc.comfortune.com

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
cnbc.comStai leggendo7 mesi fa

Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.

originale
forbes.com7 mesi fa

Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.

Leggi questa versione → originale
fortune.com7 mesi fa

Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial | Fortune

The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.

Leggi questa versione → originale
theguardian.com7 mesi fa

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Report dashes hopes for new use for blockbuster weight-loss drug

Leggi questa versione → originale
cincodias.elpais.com7 mesi fa

Novo Nordisk se desploma en Bolsa ante los malos resultados de los ensayos de uno de sus fármacos contra el…

La acción llega a caer un 12% hasta sus precios mínimos en más de cuatro años

Leggi questa versione → originale
bbc.com7 mesi fa

Obesity drug semaglutide fails to slow Alzheimer's

There were initial hopes that the drug in weight loss jab Wegovy could slow progression of dementia.

Leggi questa versione → originale

Timeline cronologica

  1. lunedì 24 novembre 2025·cnbc.com

    Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target

    Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.

  2. lunedì 24 novembre 2025·ft.com

    Novo Nordisk shares slump after drug failure in Alzheimer’s trial

    Outcome is blow to one of Europe’s largest listed companies

  3. lunedì 24 novembre 2025·cincodias.elpais.com

    Novo Nordisk se desploma en Bolsa ante los malos resultados de los ensayos de uno de sus fármacos contra el Alzhéimer

    La acción llega a caer un 12% hasta sus precios mínimos en más de cuatro años

  4. lunedì 24 novembre 2025·forbes.com

    Novo Nordisk Shares Plummet After Its Alzheimer’s Drug Trial Fails

    The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.

  5. lunedì 24 novembre 2025·theguardian.com

    Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

    Report dashes hopes for new use for blockbuster weight-loss drug

  6. lunedì 24 novembre 2025·bbc.com

    Obesity drug semaglutide fails to slow Alzheimer's

    There were initial hopes that the drug in weight loss jab Wegovy could slow progression of dementia.

  7. lunedì 24 novembre 2025·fortune.com

    Novo Nordisk stock trades at 4-year-low on the back of disappointing Alzheimer’s trial | Fortune

    The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.